The chief advantage of drug-eluting stents (DES) over bare-metal stents is that they significantly reduce the risk of restenosis. The chief disadvantages of DES are their greater cost and the requirement for prolonged dual antiplatelet therapy after DES implantation. In a study published in Archives of Internal Medicine,  Amit Amin and colleagues analyzed data from 1.5…

Click here to continue reading…